Our site is 3 years old. Thank you for your trust
51426USD

Etoricoxib Teva

SKU:1597
To favorites
Etoricoxib Teva non-steroidal anti-inflammatory drug, blocks the formation of prostaglandins and has anti-inflammatory, analgesic and antipyretic effects
Active substance:Etoricoxib
Pharmacological group:anti-inflammatory
Country of origin:Hungary
Expiration Date (in months):Always fresh
In stock
In stock
In stock
In stock
In stock
$16
We deliver goods to almost any country. Each parcel is assigned a track number
You can pay by Paypal or any card Visa or Mastercard
Discount system
Cumulative discounts and Bonus program for our clients
Original goods
We offer our customers only original products
Description
Features
Reviews

Instructions for Etoricoxib Teva

Release form

tab, film coating, 30 mg: 7, 28, 56 or 98 pcs
tab, film coating, 60 mg: 2, 7, 14, 28, 56 or 98 pcs
tab, film coating, 90 mg: 2, 7, 14, 28, 56 or 98 pcs

Description:

The tablets are covered with a blue film shell, round, double-convex, with an engraving of "30" on one side, the other side is smooth.

1 tab.
Etoricoxib 30 mg
Auxiliary substances: calcium hydrophosphate anhydrous - 38.2 mg, cellulose microcrystalline PH101 - 10.9 mg, cellulose microcrystalline PH 102 - 10.9 mg, A-type Crospovidone - 6 mg, C25 - 3 mg, magnesium stearate - 1 mg.

Film sheath composition: Aquapolish P blue 064.2 MS; (hypromellose- 1.5 mg; hydroxypropyl cellulose (hyprolose) - 0.15 mg; talc - 0.45 mg; triglycerides, medium-chain - 0.15 mg; titanium dioxide (E171) - 0.6 mg; cellulose microcrystalline- 0.1185 mg; indigocarmine-based aluminium varnish (E132) - 0.03 mg; Iron Oxide Red Dye (E172)- 0.0015 mg)

7 pcs. - foil blisters (1) - cardboard packs.
14 pcs. - foil blisters (2) - cardboard packs.
14 pcs. - foil blisters (4) - cardboard packs.
14 pcs. - foil blisters (7) - cardboard packs.

ATC codes
M01AH05 Etoricoxib

Active substance
Etoricoxib

Pharmacotherapy group
NSAIDs

Testimony Etoricoxib:

Symptomatic therapy of osteoarthrosis, rheumatoid arthritis, ankylosing spondylitis; Pain and inflammation symptoms associated with acute podagric arthritis; Short-term treatment of pain associated with dental surgery.

Method of use, course and dosage Etoricoxib:

The preparation is taken orally in a dose of 60-120 mg once/day.
Patients with liver failure (5-9 Child Pugh) are advised not to exceed a daily dose of 60 mg.

Application for kidney disorders
It is contraindicated in severe kidney failure (CC less than 30 ml/min), progressive kidney diseases.

Use in liver disorders
It is contraindicated in severe liver failure (over 9 Child Pugh) or active liver disease. Patients with moderate liver failure (5-9 Child Pugh) are advised not to exceed a daily dose of 60 mg.

Application in elderly patients
It is used with caution in elderly people.

Use in children
It is contraindicated in children and adolescents under 16 years of age.

Nosology (ICD codes)
M05
Seropositive rheumatoid arthritis
M10
Podagra
M15
Polyarthrosis
M19.9
Arthrosis unspecified
M25.5
Joint pain
M45
Ankylosing spondylitis
M47
Spondylosis
R52.0
Acute pain

Pharmacological effect Etoricoxib:

NAPS. The selective COX-2 inhibitor inhibits prostaglandin formation in therapeutic concentrations and has anti-inflammatory, analgesic and antipyretic effects.
Selective suppression of COX-2 is accompanied by a reduction in the expression of clinical symptoms associated with the inflammatory process, with no effect on platelet function and the mucosa of the gastrointestinal tract.

Features
Active substance
Pharmacological group
Country of origin
Expiration Date (in months)
No reviews yet — your comment may be first.
All reviews 0
general rating